Galectin Therapeutics Inc (USD)
GALT
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range2.86 | 3.05
52-Wk Range2.74 | 6.06
Last Close2.88
Mkt Cap (m)163.83
Dividend yield-
ISINUS3632252025
Volume262,000
Exchange VenueNAS

Company Profile

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Key Information
Price/Earning-
Price/Book3.47
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Legal Documents

Prospectus
en 30/04/2019
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)
Operating Income (m)-12-15-20-21-16-14
Net Income (m)-12-16-20-21-16-14
Basic EPS-1.30-0.78-0.88-0.76-0.49-0.38
Avg. Diluted Shares Outstanding (m)172224293639
Balance Sheet
USD201320142015201620172018
Current Assets (m)1130261649
Non Current Assets (m)
Total Assets (m)1130261649
Current Liabilities (m)221432
Total Liabilities (m)------
Total Equity (m)828251217
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)-7-12-17-16-16-10
Capital Expenditure (m)------
Figures are quoted in USD unless stated otherwise
0.00 (0.00%)
$
2.88
Last Price